Apellis Pharmaceuticals, Inc. Aktie News

WALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 8:30 a.m. ET.

WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held July 30 - August 2 in Long Beach, California. These data further demonstrate the robust efficacy and well-documented safety profile of SYFOV...

STOCKHOLM , July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® (systemic pegcetacoplan) in exchange for $275 million upfront and up to $25 million in additional milestone payments dependent on regulatory approvals in the E...

WALTHAM, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced a capped royalty purchase agreement with Sobi® under which Apellis will receive up to $300 million in exchange for 90% of Apellis' future ex-U.S. royalties for Aspaveli® (systemic pegcetacoplan). Under the companies' 2020 collaboration agreement, Apellis is eligible for tiered royaltie...

WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a l...

WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 10:40 a.m.

Apellis Pharmaceuticals is a Buy due to the significant FCF potential of SYFOVRE® and EMPAVELI®, with SYFOVRE® projected to exceed $1bn in annual sales by 2028. SYFOVRE® has shown efficacy in slowing GA progression and saw a 122% YoY sales increase in 2024, despite initial rollout issues. EMPAVELI® offers moderate sales and is in trials for additional indications, promising incremental cash flo...

A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals (APLS -5.99%) stock in the middle of the trading week. Investors didn't take this development well, and they collectively pushed down Apellis by almost 6%, on a day when the S&P 500 (^GSPC 0.43%) closed in the black with a 0.4% gain.